GlassScriptPhysician profile
Medhat Reheem
NPI 1073555397
$1,037.50
in general payments reported to CMS, 2019-2025
14 companies · $37.40 in 2025
The $37.40 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $100 · 2021: $101 · 2022: $284 · 2023: $96.20 · 2024: $57.53 · 2025: $37.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $528.05 | 2019-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $94.25 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $53.56 | 2019 | |
| Scilex Pharmaceuticals INC. | $42.42 | 2022-2023 | Ztlido |
| Shionogi INC | $38.44 | 2019 | |
| Valinor Pharma, LLC | $37.40 | 2025 | Movantik |
| Hikma Pharmaceuticals USA | $35.01 | 2022 | |
| Pfizer INC. | $34.13 | 2019 | |
| Redhill Biopharma INC. | $25.18 | 2020-2022 | |
| Ibsa Pharma INC. | $24.75 | 2022 | |
| Medtronic, INC. | $14.88 | 2021 | |
| Medtronic USA, INC. | $14.45 | 2020 | |
| Daiichi Sankyo INC. | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Medhat Reheem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.